POSTED IN NEWS | 19. MARCH 2021
Immunotherapy against cancer: phase 1 clinical trial interim analyses
The clinical trial is a randomised, double-blind, placebo-controlled phase 1 dose-escalation study of delNS/E6E7 in up to 20 women. The trial’s primary endpoint is to evaluate safety and to determine the dosage for the subsequent phase 2. First results obtained in the clinical trial have now confirmed the tolerability of the delNS-based vector delNS/E6E7 after subcutaneous administration. In the course of the study, secondary endpoints such as the removal of the HPV 16 infection and the elimination of already existing tumours and tumour cells will also be assessed.